Gen-Probe Incorporated

Gen-Probe Incorporated engages in the development, manufacture, and marketing of molecular diagnostic products and services that are used primarily to diagnose human diseases and screen donated human blood. Its women’s health product line includes APTIMA Combo 2 assay, APTIMA CT, APTIMA GC assays, and PACE family of assays to detect chlamydia and gonorrhea; APTIMA Trichomonas ASRs to detect trichomonas; APTIMA HPV assay to detect 14 sub-types of high-risk HPV associated with cervical cancer; and AccuProbe Group B Streptococcus (GBS) assay to detect GBS from culture. The company’s infectious diseases product line comprises ProFlu+ to detect influenza A, B, and Respiratory syncytial virus; ProFAST+ to detect and differentiate seasonal H1, seasonal H3, and H1N1pdm09; ProGastro Cd to detect toxigenic strains of clostridium difficile; AMPLIFIED MTD to detect mycobacterium tuberculosis; GAS Direct to detect gas directly from a throat swab; APTIMA HIV-1 and APTIMA HCV assays to detect RNA from HIV-1 and hepatitis C virus; and ASRs for quantitative HCV testing. Its blood screening products include Procleix HIV-1/HCV, Procleix Ultrio, Procleix Ultrio Plus, and Procleix WNV assays to detect HIV-1, HCV, HBV, and west nile virus in donated blood, plasma, organs, and tissues. The company also provides instrumentation and software for performing NAT assays; and genetic testing products, such as PROGENSA PCA3 and PCA3 ASRs to detect the PCA3 genes. It serves reference laboratories, public health institutions, and hospitals through its direct sales force in the United States, Canada, and Europe, as well as through distributors internationally. The company was founded in 1983 and is headquartered in San Diego, California. As of August 1, 2012, Gen-Probe Incorporated operates as a subsidiary of Hologic Inc.